对流增强递送肽纳米纤维储库延长DM1局部滞留治疗弥漫性内生型脑桥胶质瘤的联合策略
研究针对无法手术、常规化疗无效的儿童弥漫性内生型脑桥胶质瘤(DIPG),利用对流增强递送(CED)联合载荷可调的肽纳米纤维前体(NFP)作为DM1载体,在动物模型中延长药物滞留并评估疗效。结果显示NFP在脑桥滞留数周、清除半衰期60天,DM1-NFP抑制肿瘤进展,中位生存62天,优于未治疗对照(28天)和DM1治疗组(26天)。
要点
- NFP在脑桥 infusion 部位滞留数周,清除半衰期60天。
- DM1-NFP对多种胶质瘤细胞系有活性,半数抑制浓度在纳摩尔范围。
- DM1-NFP组中位生存62天,未治疗对照组28天,DM1组26天。
核心结论
- CED联合DM1-NFP可互补性绕过血脑屏障、延长药物在融合部位的滞留并维持对DIPG的有效治疗作用以改善治疗结局。
研究设计与样本
- 动物实验:使用荷原位DIPG的动物模型评估疗效,并以PET/CT实时测定89Zr-NFP在CED后的滞留。
- 体外实验:用患者来源的DIPG细胞系检测DM1-NFP的细胞毒性。
主要发现
- DM1-NFP对多种胶质瘤细胞系显示效力,半数抑制浓度值在纳摩尔范围。
- NFP在输注部位(脑桥)滞留数周,清除半衰期为60天。
- DM1-NFP抑制动物胶质瘤进展,中位生存62天,未治疗对照组28天,DM1治疗组26天。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a highly lethal malignancy that occurs predominantly in children. DIPG is inoperable and post-diagnosis survival is less than 1 year, as conventional chemotherapy is ineffective. The intact blood-brain barrier (BBB) blocks drugs from entering the brain. Convection-enhanced delivery (CED) is a direct infusion technique delivering drugs to the brain, but it suffers from rapid drug clearance. Our goal is to overcome the delivery barrier via CED and maintain a therapeutic concentration at the glioma site with a payload-adjustable peptide nanofiber precursor (NFP) that displays a prolonged retention property as a drug carrier. METHODS: The post-CED retention of 89Zr-NFP was determined in real time using PET/CT imaging. Emtansine (DM1), a microtubule inhibitor, was conjugated to NFP. The cytotoxicity of the resulting DM1-NFP was tested against patient-derived DIPG cell lines. The therapeutic efficacy was evaluated in animals bearing orthotopic DIPG, according to glioma growth (measured using bioluminescence imaging) and the long-term survival. RESULTS: DM1-NFP demonstrated potency against multiple glioma cell lines. The half-maximal inhibitory concentration values were in the nanomolar range. NFP remained at the infusion site (pons) for weeks, with a clearance half-life of 60 days. DM1-NFP inhibited glioma progression in animals, and offered a survival benefit (median survival of 62 days) compared with the untreated controls (28 days) and DM1-treated animal group (26 days). CONCLUSIONS: CED, in combination with DM1-NFP, complementarily functions to bypass the BBB, prolong drug retention at the fusion site, and maintain an effective therapeutic effect against DIPG to improve treatment outcome.
引用
- Bellat V, Alcaina Y, Tung CH, et al. A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment. Neuro Oncol. 2020. PMID: 32301996. doi:10.1093/neuonc/noaa101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。